Company news

InspireMD Inc. news in 2024

InspireMD Inc.'s news releases, calls and decks from 2024, newest first.

View company

InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025

December 11, 2024

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

December 8, 2024

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

November 24, 2024

InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update

November 11, 2024

InspireMD to Report Third Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, November 12th

November 3, 2024

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

October 14, 2024

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

October 6, 2024

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

September 15, 2024

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

August 5, 2024

InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million

June 30, 2024

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 27, 2024

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 13, 2024

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

May 6, 2024

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

March 25, 2024

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

March 5, 2024

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

February 11, 2024

InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework

January 30, 2024

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

January 2, 2024

Calls in 2024

Decks in 2024